127 research outputs found
Acidification of Northeastern USA Lakes From Rising Anthropogenic-Sourced Atmospheric Carbon Dioxide and Its Effects on Aluminum Speciation
The impact of rising atmospheric CO2 (pCO2atm) from anthropogenic activities on pH, dissolved inorganic carbon, carbonate mineral saturation, and aluminum (Al) speciation is evaluated for 18 northeastern USA lakes using polythermal, sliding activity reaction path models. pCO2atm was forced using two scenarios from the IPCC\u27s Sixth Assessment Report in which pCO2atm attains either 600 or 1,100 ppm in 2,100. Results suggest pH will decrease 0.15 and 0.32 pH units, aCO2-3 will decrease 24% and 49%, and Ωaragonite will decrease 21% and 45%, respectively. These changes are of the same magnitude as those expected for the oceans. The effects of rising pCO2atm on sub‐lethal 20% effect concentrations (i.e., EC20) of Al for brook trout (Salvelinus fontinalis) are evaluated with the biotic ligand model, which indicates Al toxicity effects will increase as pH decreases. These changes could reverse gains in water quality and fisheries health achieved since implementation of the Clean Air Act
Increased Expression of Foxj1 after Traumatic Brain Injury
Foxj1 is a member of the Forkhead/winged-helix (Fox) family of transcription factors, which is required for postnatal differentiation of ependymal cells and a subset of astrocytes in the subventricular zone. The subpopulation of astrocytes has the ability of self-renew and neurogenic potential differentiated into astrocytes, oligodendrocytes, and neurons. However, its expression and function in the central nervous system lesion are not well understood. In this study, we performed a traumatic brain injury (TBI) model in adult rats and investigated the changed expression of Foxj1 in the brain cortex. Western blot and immunohistochemistry analysis showed that the expression of Foxj1 gradually increased, reached a peak at day 3 after TBI, and declined during the following days. Double immunofluorescence staining revealed that Foxj1 was co-expressed with MAP-2 and GFAP. In addition, we detected that Ki67 had the co-localization with NeuN, GFAP, and Foxj1. All our findings suggested that Foxj1 may be involved in the pathophysiology of brain after TBI
p73: A Multifunctional Protein in Neurobiology
p73, a transcription factor of the p53 family, plays a key role in many biological processes including neuronal development. Indeed, mice deficient for both TAp73 and ΔNp73 isoforms display neuronal pathologies, including hydrocephalus and hippocampal dysgenesis, with defects in the CA1-CA3 pyramidal cell layers and the dentate gyrus. TAp73 expression increases in parallel with neuronal differentiation and its ectopic expression induces neurite outgrowth and expression of neuronal markers in neuroblastoma cell lines and neural stem cells, suggesting that it has a pro-differentiation role. In contrast, ΔNp73 shows a survival function in mature cortical neurons as selective ΔNp73 null mice have reduced cortical thickness. Recent evidence has also suggested that p73 isoforms are deregulated in neurodegenerative pathologies such as Alzheimer’s disease, with abnormal tau phosphorylation. Thus, in addition to its increasingly accepted contribution to tumorigenesis, the p73 subfamily also plays a role in neuronal development and neurodegeneration
Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations
Myelodysplastic syndromes (MDS) are often accompanied by autoimmune phenomena. The underlying mechanisms for these associations remain uncertain, although T cell activation seems to be important. Human T-lymphotropic virus (HTLV-1) has been detected in patients with myelodysplastic syndromes, mostly in regions of the world which are endemic for the virus, and where association of HTLV-1 with rheumatological manifestation is not rare. We present here the case of a 58 year old man who presented with cytopenias, leukocytoclastic vasculitis of the skin and glomerulopathy, and was diagnosed as MDS (refractory anemia with excess blasts - RAEB 1). The patient also tested positive for HTLV-1 by PCR. After 8 monthly cycles of 5-azacytidine he achieved a complete hematologic remission. Following treatment, a second PCR for HTLV-1 was carried out and found to be negative. This is the first report in the literature of a HTLV-1-positive MDS with severe autoimmune manifestations, which was treated with the hypomethylating factor 5-azacitidine, achieving cytogenetic remission with concomitant resolution of the autoimmune manifestations, as well as HTLV-1-PCR negativity. HTLV-1-PCR negativity may be due to either immune mediated clearance of the virus, or a potential antiretroviral effect of 5-azacytidine. 5-azacytidine is known for its antiretroviral effects, although there is no proof of its activity against HTLV-1 infection in vivo
p53 Regulates Cell Cycle and MicroRNAs to Promote Differentiation of Human Embryonic Stem Cells
Multiple studies show that tumor suppressor p53 is a barrier to dedifferentiation; whether this is strictly due to repression of proliferation remains a subject of debate. Here, we show that p53 plays an active role in promoting differentiation of human embryonic stem cells (hESCs) and opposing self-renewal by regulation of specific target genes and microRNAs. In contrast to mouse embryonic stem cells, p53 in hESCs is maintained at low levels in the nucleus, albeit in a deacetylated, inactive state. In response to retinoic acid, CBP/p300 acetylates p53 at lysine 373, which leads to dissociation from E3-ubiquitin ligases HDM2 and TRIM24. Stabilized p53 binds CDKN1A to establish a G1 phase of cell cycle without activation of cell death pathways. In parallel, p53 activates expression of miR-34a and miR-145, which in turn repress stem cell factors OCT4, KLF4, LIN28A, and SOX2 and prevent backsliding to pluripotency. Induction of p53 levels is a key step: RNA-interference-mediated knockdown of p53 delays differentiation, whereas depletion of negative regulators of p53 or ectopic expression of p53 yields spontaneous differentiation of hESCs, independently of retinoic acid. Ectopic expression of p53R175H, a mutated form of p53 that does not bind DNA or regulate transcription, failed to induce differentiation. These studies underscore the importance of a p53-regulated network in determining the human stem cell state
dp53 Restrains Ectopic Neural Stem Cell Formation in the Drosophila Brain in a Non-Apoptotic Mechanism Involving Archipelago and Cyclin E
Accumulating evidence suggests that tumor-initiating stem cells or cancer stem cells (CSCs) possibly originating from normal stem cells may be the root cause of certain malignancies. How stem cell homeostasis is impaired in tumor tissues is not well understood, although certain tumor suppressors have been implicated. In this study, we use the Drosophila neural stem cells (NSCs) called neuroblasts as a model to study this process. Loss-of-function of Numb, a key cell fate determinant with well-conserved mammalian counterparts, leads to the formation of ectopic neuroblasts and a tumor phenotype in the larval brain. Overexpression of the Drosophila tumor suppressor p53 (dp53) was able to suppress ectopic neuroblast formation caused by numb loss-of-function. This occurred in a non-apoptotic manner and was independent of Dacapo, the fly counterpart of the well-characterized mammalian p53 target p21 involved in cellular senescence. The observation that dp53 affected Edu incorporation into neuroblasts led us to test the hypothesis that dp53 acts through regulation of factors involved in cell cycle progression. Our results show that the inhibitory effect of dp53 on ectopic neuroblast formation was mediated largely through its regulation of Cyclin E (Cyc E). Overexpression of Cyc E was able to abrogate dp53′s ability to rescue numb loss-of-function phenotypes. Increasing Cyc E levels by attenuating Archipelago (Ago), a recently identified transcriptional target of dp53 and a negative regulator of Cyc E, had similar effects. Conversely, reducing Cyc E activity by overexpressing Ago blocked ectopic neuroblast formation in numb mutant. Our results reveal an intimate connection between cell cycle progression and NSC self-renewal vs. differentiation control, and indicate that p53-mediated regulation of ectopic NSC self-renewal through the Ago/Cyc E axis becomes particularly important when NSC homeostasis is perturbed as in numb loss-of-function condition. This has important clinical implications
Astrocytes: biology and pathology
Astrocytes are specialized glial cells that outnumber neurons by over fivefold. They contiguously tile the entire central nervous system (CNS) and exert many essential complex functions in the healthy CNS. Astrocytes respond to all forms of CNS insults through a process referred to as reactive astrogliosis, which has become a pathological hallmark of CNS structural lesions. Substantial progress has been made recently in determining functions and mechanisms of reactive astrogliosis and in identifying roles of astrocytes in CNS disorders and pathologies. A vast molecular arsenal at the disposal of reactive astrocytes is being defined. Transgenic mouse models are dissecting specific aspects of reactive astrocytosis and glial scar formation in vivo. Astrocyte involvement in specific clinicopathological entities is being defined. It is now clear that reactive astrogliosis is not a simple all-or-none phenomenon but is a finely gradated continuum of changes that occur in context-dependent manners regulated by specific signaling events. These changes range from reversible alterations in gene expression and cell hypertrophy with preservation of cellular domains and tissue structure, to long-lasting scar formation with rearrangement of tissue structure. Increasing evidence points towards the potential of reactive astrogliosis to play either primary or contributing roles in CNS disorders via loss of normal astrocyte functions or gain of abnormal effects. This article reviews (1) astrocyte functions in healthy CNS, (2) mechanisms and functions of reactive astrogliosis and glial scar formation, and (3) ways in which reactive astrocytes may cause or contribute to specific CNS disorders and lesions
Overview of cattle diseases listed under category C, D or E in the animal health law for wich control programmes are in place within Europe
13 páginas, 5 figuras, 3 tablas.The COST action “Standardising output-based surveillance to control non-regulated
diseases of cattle in the European Union (SOUND control),” aims to harmonise the results
of surveillance and control programmes (CPs) for non-EU regulated cattle diseases to
facilitate safe trade and improve overall control of cattle infectious diseases. In this paper
we aimed to provide an overview on the diversity of control for these diseases in Europe.
A non-EU regulated cattle disease was defined as an infectious disease of cattle with no
or limited control at EU level, which is not included in the European Union Animal health
law Categories A or B under Commission Implementing Regulation (EU) 2020/2002.
A CP was defined as surveillance and/or intervention strategies designed to lower the
incidence, prevalence, mortality or prove freedom from a specific disease in a region
or country. Passive surveillance, and active surveillance of breeding bulls under Council
Directive 88/407/EEC were not considered as CPs. A questionnaire was designed to
obtain country-specific information about CPs for each disease. Animal health experts
from 33 European countries completed the questionnaire. Overall, there are 23 diseases
for which a CP exists in one or more of the countries studied. The diseases for which
CPs exist in the highest number of countries are enzootic bovine leukosis, bluetongue,
infectious bovine rhinotracheitis, bovine viral diarrhoea and anthrax (CPs reported by
between 16 and 31 countries). Every participating country has on average, 6 CPs
(min–max: 1–13) in place. Most programmes are implemented at a national level (86%)
and are applied to both dairy and non-dairy cattle (75%). Approximately one-third
of the CPs are voluntary, and the funding structure is divided between government
and private resources. Countries that have eradicated diseases like enzootic bovine
leukosis, bluetongue, infectious bovine rhinotracheitis and bovine viral diarrhoea have
implemented CPs for other diseases to further improve the health status of cattle in their
country. The control of non-EU regulated cattle diseases is very heterogenous in Europe.
Therefore, the standardising of the outputs of these programmes to enable comparison
represents a challenge.Peer reviewe
Unusual association between increased bone resorption and presence of paroxysmal nocturnal hemoglobinuria phenotype in multiple myeloma
Paroxysmal nocturnal hemoglobinuria (PNH) clones deficient in
glycosylphosphatidylinositol-anchored molecules, including CD55 and
CD59, have been previously described in patients with multiple myeloma
(MM). The aim of this study was to investigate the possible association
between existence of the PNH phenotype and myeloma bone disease.
Forty-three patients with newly diagnosed MM were the subjects of the
study. Radiographic evaluation of the skeleton was performed in all
patients at diagnosis. The following biochemical markers were measured:
bone resorption markers (tartrate-resistant acid phosphatase isoform 5b
[TRACP-5b]and N-terminal cross-linking telopeptide of type-I collagen
[NTX]), bone formation markers (bone alkaline phosphatase [bALP] and
osteocalcin [OC]), osteoprotegerin (OPG), soluble receptor activator
of nuclear factor kappaB ligand (sRANKL), and interleukin 6 (IL-6).
Detection of CD55- and/or CD59-deficient red cell populations was
performed after diagnosis. Patients with MM had elevated mean baseline
NTX, TRACP-5b, sRANKL, and IL-6 levels compared with controls, whereas
the mean values of bALP, OC, and OPG were significantly decreased. Four
patients had no osteolytic lesions, whereas 8 patients had 1 to 3 lytic
lesions, and 31 patients had more than 3 lytic lesions and/or pathologic
fractures in the skeletal survey. CD55- and/or CD59-deficient red cell
populations were observed in 56% of patients with MM. There was a
strong correlation between the presence of PNH-like erythrocytes and
increased bone resorption, as measured by NTX, TRACP-5b, and sRANKL/OPG
ratio (P <.03, P <.02, and P <.02, respectively). There was also a
significant correlation between PNH phenotype and severe bone disease (P
<.02). These results suggest that there is a possible link between PNH
phenotype and increased osteoclastic activity in MM owing to a potential
effect of myeloma microenvironment on a preexisting PNH clone. Further
studies are required for clarifying this phenomenon and investigating
possible mechanisms of this unusual association. (C) 2003 The Japanese
Society of Hematology
- …